⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
EcoVadis Joins European Commission's AI Act Advisory Forum to Shape Future of Responsible AI
prnewswire.com
JNJ
UL
JPM
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
businesswire.com
JNJ
Over 100 Organizations Thank America’s Blood Donors on World Blood Donor Day
globenewswire.com
JNJ
ABT
New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma
globenewswire.com
JNJ
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
prnewswire.com
JNJ
Patient Monitoring Devices Market worth $76.11 billion by 2031 | MarketsandMarkets™
prnewswire.com
MDT
ABT
DXCM
GEHC
BSX
MASI
BIIB
AMGN
GILD
BMY
MRK
PFE
JNJ
BAX
BOSC
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026
globenewswire.com
SNY
JNJ
Antibody Partnering Surges into 2026: Q1 Deals Top $36 Billion as Bispecifics and Discovery Platforms Drive Competition
globenewswire.com
ABBV
LLY
MRK
NVS
PFE
SNY
GILD
BMY
JNJ
UCB
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
businesswire.com
JNJ
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
prnewswire.com
JNJ